More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-MEL-26: Human Melanoma Cell Line



SK-MEL-26 is one of a series of melanoma cell lines established from patient-derived tumor samples. This cell line expresses mutant B-Raf (V600E) and wildtype N-Ras. SK-MEL-26 cells form tumors in immunocompromised mice.


This cell line was established in 1975 from a subcutaneous malignant melanoma on the right leg of a 54-year-old Caucasian female.


  • Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Toshitada Takahashi, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  • Gomi K et al. (1984) Antitumor effect of human recombinant interferon-beta against human melanomas transplanted into nude mice. Journal of Pharmacobiodynamics 7: 951-961 (PubMed ID: 6533284)
  • Fujino M et al. (1999) Effects of protein kinase inhibitors on radiation-induced WAF1 accumulation in human cultured melanoma cells. British Journal of Dermatology 141: 652-657 (PubMed ID: 10583112)
  • Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. Oncogene 31(4): 446-457 (PubMed ID: 21725359)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078,
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354,

Stage of Development

Ready to use